Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

ClinicalTrials.gov ID: NCT05100862

Public ClinicalTrials.gov record NCT05100862. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 12, 2026, 4:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R\^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.

Study identification

NCT ID
NCT05100862
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
BeOne Medicines
Industry
Enrollment
799 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 9, 2022
Primary completion
Jun 30, 2028
Completion
May 31, 2030
Last update posted
Sep 10, 2026

2022 – 2030

United States locations

U.S. sites
50
U.S. states
25
U.S. cities
46
Facility City State ZIP Site status
Ucsf Fresno University of California San Francisco Fresno Fresno California 93730-3595
Kaiser Permanente Southern California Irvine California 92618-3734
Cancer and Blood Specialty Clinic Los Alamitos California 90720-3302
Los Angeles Cancer Network Los Angeles California 90017-4803
Valkyrie Clinical Trials Los Angeles California 90067-2011
UCLA Hematologyoncology Los Angeles California 90095-3075
Scripps Health San Diego California 92103-2106
Sharp Healthcare Sharp Memorial Hospital San Diego California 92123-2701
Baptist Md Anderson Cancer Center Jacksonville Florida 32207-8432
Ascension Sacred Heart Pensacola Florida 32504-8615
Northwest Georgia Oncology Centers Marietta Marietta Georgia 30060-1152
Cancer Care Specialists of Illinois Decatur Illinois 62526-5858
Fort Wayne Medical Oncology and Hematology Fort Wayne Indiana 46804
Mission Cancer and Blood Waukee Iowa 50263
Cotton Oneil Cancer Center Topeka Kansas 66606-1535
Cancer Center of Kansas Wichita Kansas 67214-3728
Baptist Health Lexington Lexington Kentucky 40503-1466
Christus Highland Cancer Treatment Center Shreveport Louisiana 71105-6800
Luminis Health Anne Arundel Medical Center Annapolis Maryland 21401
The University of Maryland Greenebaum Comprehensive Cancer Center Baltimore Maryland 21201
Ascension St Agnes Hospital Baltimore Maryland 21229-5201
American Oncology Partners of Maryland Pa Bethesda Maryland 20817-7847
Henry Ford Hospital Detroit Michigan 48202-2608
Corewell Health the Michigan Cancer Consortium Grand Rapids Michigan 49503-2560
Hattiesburg Hematology and Oncology Clinic Hattiesburg Mississippi 39401-7233
University of Missouri Hospital Ellis Fischel Cancer Center Columbia Missouri 65212-1000
Oncology Hematology Associates Springfield Missouri 65807-5288
St Vincent Frontier Cancer Center Billings Montana 59102-6746
Nebraska Cancer Specialists Omaha Nebraska 68130-2042
Comprehensive Cancer Centers of Nevada Las Vegas Nevada 89169-3321
Iyengar Hematology Oncology Medical Center Pa Bayonne New Jersey 07002-4654
Summit Medical Group Florham Park New Jersey 07932-1049
New York Cancer and Blood Specialists Shirley New York 11967
Suny Upstate Medical University Syracuse New York 13210-2306
North Shore Hematology Oncology Associates Eccc Bronx The Bronx New York 10469-5930
Optum Medical Care, Pc Westbury New York 11590-5119
Levine Cancer Institute Wake Forest Charlotte North Carolina 28204-2990
Oncology Hematology Care Clinical Trials, Llc Cincinnati Ohio 45245-1995
Va Northeast Ohio Healthcare System Cleveland Ohio 44106-1702
Toledo Clinic Cancer Center Toledo Ohio 43623-3536
Mainline Health Lankenau Institute For Medical Research Wynnewood Pennsylvania 19096
Cancer Care Associates of York York Pennsylvania 17403-5049
Prairie Lakes Healthcare System Watertown South Dakota 57201-1548
Tennessee Oncology Nashville St Thomas Midtown Clinic Nashville Tennessee 37205
Texas Oncology Baylorcharles A Sammons Cancer Center Dallas Texas 75246-2003
Md Anderson Cancer Center Houston Texas 77030-3907
Northeast Texas Cancer and Research Institute Tyler Texas 75702-7522
University of Washington Seattle Washington 98195
Medical Oncology Associates Spokane Washington 99208-1129
Northwest Medical Specialties Tacoma Washington 98405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 214 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05100862, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 10, 2026 · Synced Sep 12, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05100862 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →